Laxxon Medical: Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Using their SPID®-Technology, Laxxon Medical has manufactured a 3D printed oral tablet combining a GLP-1 receptor agonist and a permeation enhancer intended to increase bioavailabilityLXM.2 is being developed
Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In Canada finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV.
Hyloris Enrolls First Patient In Phase 3 Clinical Trial For Its Proprietary Mouth Rinse To Control Incidences Of Bleeding Related To Dental Procedures menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.